Regional office - Australia
95 Pitt Street
Tel: +61 (0)2 8249 8342
Regional office - New Zealand
Edison Investment Research (NZ) Ltd
PO Box 10293
Tel: +61 (0)2 8249 8342
listed companiesSee more
Companies with HQs in asia-pacificSee more
Alternative Energy | 12/06/2019
Sarah Baker, head of North American strategic engagement at the London Stock Exchange, and Ian McLelland, global head of natural resources for Edison Group, discuss how North American resources companies are increasingly seeking access to the diverse and sophisticated pools of investment capital in the UK. They outline recent examples and offer advice on how to best unlock additional pools of accessible capital.
Oil & gas | 11/06/2019
The focus for Liquefied Natural Gas (LNGL) remains the signature of long-term offtake contracts for Magnolia LNG, the company’s flagship LNG export terminal in Lake Charles, Louisiana. In March 2019, authorisation was received from the US Department of Energy (DOE) for expansion of export capacity to 8.8Mtpa (from 8.0Mtpa) to free trade agreement (FTA) countries. Management expects FERC approval and non-FTA consent from the DOE to follow shortly. Edison’s valuation has been updated to…
Mining | 11/06/2019
Julian Hanna (MD) and Jacques Janse Van Rensburg (executive manager, business development) of MOD Resources discuss the results of its feasibility study at the T3 Copper Project, located in Botswana. They also look at potential exploration upside at the project and the next steps for the company.
Pharmaceuticals & healthcare | 11/06/2019
Pacific Edge recently reported FY19 results, including 12.3% growth in Cxbladder sales compared to FY18. These sales exclude tests for patients covered by the US Centers for Medicare and Medicaid Services (CMS), which currently account for approximately 50% of lab throughput. Total lab throughput increased by 8.6% during the year, with Q419 up 26% compared to Q418 and up 12% compared to the prior quarter. Rest of world (ROW) throughput (which represents 20% of the total) increased by 126% in the…
Food & Drink | 10/06/2019
Edison Investment Research is terminating coverage on Xbrane Biopharma, Is Private Equity, Max 21, Elk Petroleum and Centrale del Latte d'Italia. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.